Sch-27899 Schering-Plough Corp

IDrugs

Volumn 2, Issue 5, 1999, Pages 446-453

  Maertens, J A ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; EVERNIMICIN; ORITAVANCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; CLINICAL TRIAL; DRUG CONFORMATION; DRUG EFFICACY; DRUG ISOLATION; DRUG POTENCY; DRUG SAFETY; ERYTHEMA; GRAM NEGATIVE INFECTION; HUMAN; INJECTION PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0032893543     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. 163490 In vitro evaluations of everninomycin (Sch-27899), a novel antimicrobial agent with a wide spectrum against clinically important gram-positive pathogens Jones RN, Barrett MS, Erwin ME ICAAC1994 34th Oriando Abs F126 • Report on the in vitro activity of Sch-27899 against a wide spectrum of clinically important Gram-positive pathogens.
2. 163491 Pharmacokinetics of everninomicin (Sch-27899) in mice, rats, rabbits and cynomolgus monkeys LJn C, Nomeir A, Urn J, Loebenberg D, Hare R, Miller GH ICAAC 1994 34th Oriando Abs F128 • For eveminomicin doses adjusted to 60 mg/kg, the AUC values in order are: monkeys rabbits rats mice. Thus higher systemic exposure occurs with larger animals.
3. 183766 Everninomicin, a new oligosaccharide antibiotic: its antimicrobial activity, post-antibiotic effect and synergistic bactericidal activity. Nakashio S, Iwasawah H, Dun FY, Kanemitsu K, Shimada J DRUGS EXP CLIN RES 1995 21 1 7-16 • Report on the antimicrobial activity, post-antibiotic effect and synergistic bacterial activity of eveminomicin. Report on the antimicrobial activity of Sch-27899.
4. 189296 Preliminary interpretive criteria for disk diffusion susceptibility testing of everninomicin Cormican MG, Marshall SA, Jones RN ICAAC 1995 35th San Francisco Abs D31
5. 189879 Upjohn antibiotics show promise SCRIP 1995 2068 22
6. 204062 Comparative in-vitro activity of Sch-27899, a novel everninomicin, and vancomycin Urban C, Mariano N, Mosinka Snipas K, Wadee C, Chahrour T, Rahal JJ J ANTIMICROB CHEMOTHER1996 37 2 361-364
7. 211855 S-Plough R&D update SOT/P1996 2136 8
8. 217592 New approaches to the treatment of vancomycinresistant bacterial infections. Malabarba A EXP OPIN THER PAT 199667627-644
9. 220173 Emerging resistance to antimicrobial agents in Grampositive bacteria: enterococci, staphyiococci and nonpneumococcal streptococci Cormican MG, Jones RN DRUGS 1996 51 Suppl 1 6-12
10. 221637 Schering-Plough Addresses analyst group on pharmaceutical business research progress. Schering Plough Corp PRESS RELEASE 1996 October 3
11. 222118 New directions in antibacterial research Chu DTW, Plattner JJ, Katz L J MED CHEM1996 39 20 3853-3874 • A discussion of different approaches to the discovery of novel antibacterial.
12. 223270 Comparative in vitro activities of a new oligosaccharide, everninomicin, against clinical enterococci Wiiley BM, Sachse L, Mustachi B, McGeer A, Low DE ICAAC1996 36th New Orleans Abs F237
13. 223276 In vitro activity of Sch-27899 against aerobic and anaerobic gram-positive bacteria, Haemophilus influenzae, and Moraxella. Chin NX, Neu HC ICAAC 1993 33rd New Orleans 204
14. 223277 In vitro activity of everninomicin (Sch-27899). Nishino T, Sakurai M ICAAC 1993 33rd New Orleans 203
15. 223278 Comparative antimicrobial activity of everninomicin (Sch-27899), a new oligosaccharide antibiotic, against recent clinical isolates. Nakashio S, Iwasawa H, Hori S, Shimada J ICAAC 1993 33rd New Orleans 203
16. 223279 Sch-27899, an everninomicin active against multiplyresistant enterococci and staphylococci. Shlaes DM, Shlaes JH, Etter L, Hare RS, Miller GH ICAAC 1993 33rd New Orleans 203
17. 223848 Preliminary interpretive criteria for disk diffusion susceptibility testing of Sch-27899, a compound in the everninomicin class of antimicrobial agents Cormican MG, Marshall SA, Jones RN DIAGN MICROB1OL INFECT DIS 1995 23 4 157-160
18. 223849 In vitro antibacterial activities of everninomicin (Sch27899) compared with vancomycin and teicoplanin against clinical isolates of staphylococci Masmoudi A, Caillon J, Mazeau C, Minozzi C, Miller G, Bismuth R ICAAC 1993 33rd New Orleans 203
19. 223850 In vitro antibacterial activities of everninomicin (Sch27899), a novel oligosaccharide antibiotic. Goto S, Yamaguchi K, Kaneko Y, Tsuji A, Miyazaki S ICAAC 1993 33rd New Orleans 204
20. 223852 Comparative in vitro activity of (Sch-27899), a novel everninomicin Urban C, Mariano N, Mosinkasnipas K, Wadee C, Chahrour T, Rahal JJ ICAAC 1993 33rd New Orleans 203
21. 223853 In vitro activity of Sch-27899 on Clostridium difficile at various pHs Mortsell E, Hagelberg A, Dombusch K ICAAC 1993 33rd New Orleans 202
22. 223854 Biological activity of Sch-27899, an everninomicin antibiotic Loebenberg D, Cacciapuoti A, Naples L, Moss EL Jr, Menzel F Jr, Hare RS, Miller GH ICAAC 1993 33rd New Orleans 202
23. 223855 Stereoselective alpha-glycosylation of nitro sugar evernitrose: synthesis of the terminal AB unit of everninomicin antibiotics Juetten P, Scharf HD, Raabe G J ORG CHEM1991 56 257144-7149
24. 223857 The structure of new oligosaccharide antibiotics, 13384 components 1 and 5 Ganguly AK, Pramanik B, Chan TM, Sarre O, LJu YT, Morton J, Girijavallabhan V HETEROCYCLES 1989281 83-88
25. 223880 Antimicrobial activity of SCH-27899, oligosaccharide member of the everninomycin class with a wide gram-positive spectrum Jones RN, Barrett MS CLIN MICROBIOL INFECT 1995 1 135-43
26. 237334 Schering-Plough Corp ANNUAL REPORT 1996
27. 242435 Schering-Plough to boost R&D spend. SCRIP 1997 2221 13
28. 247252 Schering-Plough Reviews Research and Business Progress, Sharpens 1997 Earnings Projection Schering Plough Corp PRESS RELEASE 1997 May 21
29. 265174 Current approaches to overcome bacterial resistance Setti EL, Quattrocchio L, Micetich RG DRUGS FUTURE 1997 22 3 271-284
30. 265280 Interscience Conference on Antimicrobial Agents and Chemotherapy 37th Annual Meeting (Part II), Poster Session, Toronto, Ontario, Canada IDdb MEETING REPORT 1997 Sepembert 28-October 1
31. 265423 Schering-Plough Reports Third Quarter 1997 EPS, Announces $1 Billion Share Buyback Program, Reviews Research and Development Progress Schering Plough Corp PRESS RELEASE'1997 October 7
32. 266882 Vancomycin resistance a global reality SCRIP 1997 227716-17
33. 269182 Interscience Conference on Antimicrobial Agents and Chemotherapy: 37th Annual Meeting (Part V), Toronto, Ontario, Canada IDdb MEETING REPORT 1997 September 28-October 1
34. 277513 ABN AMRO Hoare Govett - Antibiotic therapeutic review Colletta A, Brewer M, Beadle D, Brindle S ANALYST REPORT 1998 February
35. 281013 Schering-Plough Corp ANNUAL REPORT 1997 December
36. 281057 Pharmaceutical Industry: Global Model Book Highlights: Models for the US, Europe, Emerging Europe and Japan. Merrill Lynch ANALYST REPORT 1998
37. 285920 Comparative bactericidal kinetics of everninomicin (Sch-27889) at various dosages in a pharmacodynamic model Vesga O, Craig WA ICAAC 1997 37th Toronto A-30
38. 285921 In vivo pharmacodynamic activity of Sch-27899 (Ziracin) an everninomicin antibiotic. Bauemfeind A, Eberlein E, Jungwirth R ICAAC 1997 37th Toronto Abs A-32 • Report on the in vivo pharmacodynamic activity of Sch-27899.
39. 286448 Pharmacokinetics and metabolism of [C]Sch-27899 (Ziracin) in rats and monkeys Krieter P, Thonoor M, Wirth M, Gupta S, Patrick J, Cayen MN ICAAC1997 37th Toronto A-112
40. 286455 Effect of gender on the pharmacokinetics of Ziracin (Sch27899) in healthy volunteers. Menon S, Pai S, Banfield CR, Cayen M, Affrime MB, Batra V ICAAC 1997 37th Toronto A-113 • Report on the pharmacokinetics of a single-dose of Sch-27899 in healthy volunteers and the effect of gender.
41. 286456 Multiple-dose safety, tolerance and pharmacokinetics of Ziracin (Sch-27899): A new, novel oligosaccharide antibiotic Banfield CR, Glue P, Affrime MB, Rannery BF, Pai S, Menin S, Batra V, Rudewicz P ICAAC 1997 37th Toronto A-114 • Report on the safety, tolerance and pharmacokinetics of Sch-27899 multiple-dosing in volunteers.
42. 286515 Efficacy of Sch-27899 (Ziracin) against bacterial Infections in mice. Menzel F, Noms C, Michalski M, Corcoran E, Moss EL, Cacciapuoti AF, Loebenberg D, Hare RS, Miller GH ICAAC 1997 37th Toronto B-98
43. 286637 In vitro activity of Sch-27899 and other antimicrobials against Borrelia spp. Dever LL, Barbour AG ICAAC 1997 37th Toronto E-26
44. 292436 Schering oncology collaborations produce three phase III compounds FDC REPORTS PINK SHEET 1998 60 28 20
45. 293117 Novel anti-staphylococcal targets and compounds. Labischinski H, Entert K, Wieland B EXP OP1N INVEST DRUGS 1998 7 8 1245-1256
46. 296972 Single-Dose Safety, Tolerance, and Pharmacokinetics of Sch-27899 (Ziracin) In Healthy Male Japanese Volunteers Uematsu T, Kozawa O, Nagashima S, Kanamaru M, Ochi Y ICAAC 1998 38th San Diego Abs A48
47. 296974 Effect of Renal Insufficiency on the Single-Dose Pharmacokinetics (PK) of Sch-27899 (Ziracin) Banfield C, Pai S, Swan SK, Lambrecht L, Laughlin M, Affrime M ICAAC 1998 38th San Diego Abs A50
48. 297207 Efficacy of Ziracin (Sch-27899) in a Mouse Model of Pneumococcal Pneumonia Wang E, Bergeron Y, Simard M, Cote Richer M, Bergeron MG ICAAC 1998 38th San Diego Abs B40 • Report on efficacy of Sch-27899 in a mouse model of pneumococcal pneumonia, including pharmacokinetic analysis.
49. 297211 In Vivo Activities of Sch-27899 (Ziracin) in a Murine Model of Hematogeneous Pulmonary Infectious Induced by Staphylococcus aureus Enmeshed in Agar Beads Tomono K, Tomiyama Y, Hirakata Y, Maesaki S, Tashiro T, Kohno S ICAAC 1998 38th San Diego Abs B43
50. 297213 Efficacy of Ziracin (Sch-27899), a New Everninomicin Antibiotic, against a Replicative Legionella pneumophila Lung Infection in Mice Brieland JK, Loebenberg D, Menzel F, Caccia Puoti A, Hare R ICAAC 1998 38th San Diego Abs B44
51. 297418 Physiological Investigation on the Mechanism of Action of Sch-27899 (Ziracin) Black TA, Zhao W, Shaw KJ, Hare S ICAAC 1998 38th San Diego Abs C106
52. 297422 Ribosomal Protein L16: the Putative Target Site for Everninomicin (Sch-27899) Action in Streptococcus pneumoniae Adrian PV, Wugman KP ICAAC 1998 38th San Diego Abs C110
53. 297754 Activity and Spectrum of Ziracin (Sch-27899) Tested against Nonfastidious Gram-Positive Species Including Recommendations for Routine Susceptibility Test Methods Jones RN, Marshall SA, Pfaller MA, Doem GV, Erwin ME ICAAC 1998 38th San Diego Abs D58
54. 297770 Antimicrobial Activity of Ziracin (Sch-27899) against Streptococcus Species Tested by Disk Diffusion and Three Dilution Methods Marshall SA, Jones RN, Erwin ME, Pfaller MA, Doem GVICAAC1998 38th San Diego Abs D68
55. 298111 In Vitro Activity of Ziracin (Sch-27899) against Chlamydia pneumonlae and C trachomatis Roblin PM, Reznik T, Kutlin A, Hammerschlag MR ICAAC 1998 38th San Diego Abs E111
56. 298112 In vitro antibacterial activity of Sch-27899 (Ziracin) against Gram-positive cocci. Sato Y, Kuga A, Okamoto R, Inoue M ICAAC 1998 38th San Diego Abs E-112
57. 298113 In Vitro Activity of Everninomicin-Derivative Sch-27899 (Ziracin) and Other Agents against Anaerobic Bacteria Tanaka K, Kalo N, Watanabe K ICAAC 1998 38th San Diego Abs E113 • Report on in vitro activity of Sch-27899 and other agents against anaerobic bacteria.
58. 298114 Evaluation of Antimicrobial Activities of Sch-27899 (Everninomicin, Ziracin) for Legionella spp Takemura H, Ikejima H, Kunishima H, Terakubo S, Kanemitsu K, Yamamoto H, Kaku M, Shimada J ICAAC 1998 38th San Diego Abs E114
59. 298115 In Vitro Activity of Sch-27899 (Everninomicin, Ziracin) and Seven Other Antimicrobial Agents against Mycoplasma pneumoniae Ikejima H, Yamamoto H, Kunishima H, Terakubo S, Takemura H, Kanemitsu KL, Ishida K, Kaku M, Shimada J ICAAC 1998 38th San Diego Abs E115
60. 298116 In Vitro Evaluation of Antimicrobial Activities of Sch27899 (Everninomicin, Ziracin) against Gram-Positive Cocci Using Etest Terakubo S, Takemura H, Yamamoto H, Ikejima H, Kunishima H, Kanemitsu K, Kaku M, Shimada J ICAAC 1998 38th San Diego Abs E116
61. 298117 Comparative In Vitro Sensitivity of Borrelia burgdorferi to Ziracin (Sch-27899), Penicillin, and Ceftriaxone Pavia C, Wormser G, Nowakowski J, Caccia Puoti A ICAAC 1998 38th San Diego Abs E117
62. 298118 In Vitro Activity of Ziracin (Sch-27899) Alone and in Combination with Other Antimicrobial Agents Fuchs PC, Barry AL, Brawn SD ICAAC 1998 38th San Diego Abs E118
63. 298119 The In Vitro Antimicrobial Activity of Ziracin (Sch27899) Compared with Selected Antibiotics against a Range of Recently Isolated Gram-Positive Bacteria Hare RS, Sabatelli FJ ICAAC 1998 38th San Diego Abs E119
64. 298120 In Vitro Activity of Everninomicin (Ziracin), a New Injectable Antibiotic, against Clinically Isolated Strains Including Vancomycin Low-Resistant Staphylococcus aureus and VRE Murakami H, Hanaki H, Sasaki K, Inaba Y, Hori N, Hiramatsu K ICAAC 1998 38th San Diego Abs E120
65. 298121 In Vitro Activities of Ziracin (Sch-27899), Levafloxacin and Three Other Quinolones against S pneumoniae Manzor O, Saravolatz L /CAAC1998 38th San Diego Abs E121
66. 298122 In Vitro Activity of Sch-27899 (Ziracin) against 104 Legionella spp Edelstein PH, Edelstein MAC, Ren J ICAAC 1998 38th San Diego Abs E122 • Report on in vitro activity of Sch-27899 against Legionella species.
67. 298123 Activity of H MR-3647 Compared to 4 Macrolides and Pristinamycin against H Influenzae and M catarrhalis by MIC Hoellman DB, Bajaksouzian S, Jacobs MR, Appelbaum PC ICAAC 1998 38th San Diego Abs E123
68. 298131 Susceptibility Testing of Rapidly Growing Mycobacleria to a New Everninomicin, Ziracin (Sch-27899) Brown BA, Onyi GO, Wallace Jr RJ ICAAC1998 38th San Diego Abs E128 • Report on susceptibility testing of rapidly growing mycobacteria to Sch-27899.
69. 299113 Antagonists acting at the NMDA receptor complex: potential for therapeutic applications Jane DE INT SYMP MED CHEM199815th Edinburgh D 1
70. 299142 Cystitis antibiotic treatment should last three days-UK report FDC REPORTS PINK SHEET 1998 60 37 15-16
71. 301421 New synthetic technology for the stereocontrolled construction of 1,1'-disaccharides and 1,1':1,2-Trisaccharides. Synthesis of the FG ring system of everninomicin 13,384-1. Nicolaou KC, Van Delft FL. Conley SR, Mitchell HJ, Jin 2, Rodgriguez RM J AM CHEM SOC1997 119 38 9057-9058
72. 301422 Determination of the absolute stereochemistry at the C16 orthoester of everninomicin antibiotics; a novel acidcatalyzed isomerization of orthoesters. Ganguly AK, McCormick JL, Chan T. M, Saksena AK, Das PR TETRAHEDRON LETT 1997 38 46 7989-7992
73. 301423 Structure elucidation of everninomicin-6, a new oligosaccharide antibiotic, by chemical degradation and FABMS methods. Barther P, Pramanik BN, Saksena AK, Tu Y. H, Das PR, Sarre O, Ganguly AK J AM SOC MASS SPECTROM1997 8 11 1134-1140
74. 301468 Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomicin (Sch-27899), and resistance to an antibiotic used for growth promotion in animals, avilamycin. Aarestrup FM MICROBIAL DRUG RESISTANCE 1998 4 2 137-141 • Report on the occurrence of enterococci with decreased susceptibility to Sch-27899 in Denmark.
75. 301567 Interscience Conference on Antimicrobial Agents and Chemotherapy: 38th Annual Meeting (Part VI) San Diego, CA, USA IDdb MEETING REPORT 1998 September 34-27 • Report on the absence of synergism or antagonism of Sch-27899 with other protein synthesis inhibitors and lack of cross-resistance by organisms resistant to other protein synthesis inhibitors.
76. 308363 38th ICAAC, September 24-27 1998, San Diego, US Discotto LF, Pucci MJ, Lawrence LE, Barrett JF EXP OPIN INVEST DRUGS 1998 7 12 2061-2077
77. 312241 Everninomicin, a new antibiotic complex from Micromonospora carbonacea. Weinstein MJ, Luedemann GM, Oden EM. Wagman GH ANTIMICROB AGENTS CHEMOTHER 196524-32 • Initial report describing the isolation of the everinomicins.
78. 312243 Probing the functional role and localisation of Escherichia coli ribosomal protein L16 with a monoclonal antibody. Nag B, Glitz DG, Tewari DS, Traut RR J BIOL CHEM 1991 26611116-11121 • Study mapping the position of RPL16 (in Escherichia coli) to the interface between the small and large subunit of the ribosome.
79. 312244 A double-blind, randomized, multicenter study of Ziracin versus ceftriaxone In patients with S pneumoniae pneumonia. Tsitsi JML, Calver AD, Luke B, Garaud JJ, Print P, Gupte J, Wherry JC ICAAC 1998 38th San Diego Abs L-109